NHS watchdog imposes $84M fine on Pfizer, Flynn Pharma in newest development of price-gouging saga
Ten years after two companies allegedly started to price-gouge the UK healthcare system, another fine has been levied.
The UK government put out word Thursday that Pfizer and UK biotech Flynn Pharma were fined 70 million pounds ($84 million) by the country’s antitrust watchdog for overcharging the National Health Services (NHS) for epilepsy drug Epanutin.
And there’s some history here. The Competition and Markets Authority (CMA) had originally fined Pfizer and Flynn close to 90 million pounds in 2016 for inflating prices for Epanutin by as much as 2,600% — rivaling Martin Shkreli’s infamous 2015 price hike of Daraprim by 5,000%.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.